Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC)

被引：21
|
作者：
Barroso-Sousa, Romualdo
Li, Tianyu
Reddy, Sangeetha
Emens, Leisha A.
Overmoyer, Beth
Lange, Paulina
Dilullo, Molly K.
Attaya, Victoria
Kimmel, Jeffrey
Winer, Eric P.
Mittendorf, Elizabeth A.
Tayob, Nabihah
Tolaney, Sara M.
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-GS2-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GS2-10
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Nimbus: A phase II study of nivolumab plus ipilimumab in metastatic hypermutated HER2-negative breast cancer.
    Barroso-Sousa, Romualdo
    Trippa, Lorenzo
    Lange, Paulina
    Andrews, Chelsea
    McArthur, Heather L.
    Haley, Barbara B.
    Rugo, Hope S.
    Emens, Leisha A.
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Genomic determinants of benefit to nivolumab (NIVO) plus low dose ipilimumab (IPI) among patients (pts) with hypermutated HER2negative metastatic breast cancer (MBC): results of NIMBUS trial
    Barroso-Sousa, Romualdo
    Chinsky, Tyler
    Li, Tianyu
    Reddy, Sangeetha
    Emens, Leisha
    Overmoyer, Beth
    AlDubayan, Saud
    Chu, Hoyin
    Lange, Paulina
    Kasparian, Julie
    Basta, Ameer
    DiLullo, Molly
    Attaya, Victoria
    Hughes, Melissa
    Lin, Nancy
    Tayob, Nabihah
    Jeselsohn, Rinath
    Mittendorf, Elizabeth
    Tolaney, Sara
    CANCER RESEARCH, 2024, 84 (09)
  • [3] Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial
    Torres, Evanthia. T. Roussos
    Ho, Won J.
    Danilova, Ludmila
    Tandurella, Joseph A.
    Leatherman, James
    Rafie, Christine
    Wang, Chenguang
    Brufsky, Adam
    LoRusso, Patricia
    Chung, Vincent
    Yuan, Yuan
    Downs, Melinda
    OConnor, Ashley
    Shin, Sarah M.
    Hernandez, Alexei
    Engle, Elizabeth L.
    Piekarz, Richard
    Streicher, Howard
    Talebi, Zahra
    Rudek, Michelle A.
    Zhu, Qingfeng
    Anders, Robert A.
    Cimino-Mathews, Ashley
    Fertig, Elana J.
    Jaffee, Elizabeth M.
    Stearns, Vered
    Connolly, Roisin M.
    NATURE CANCER, 2024, 5 (06) : 866 - 879
  • [4] EVOLUTION OF CHEMOTHERAPY OPTIONS IN HER2-NEGATIVE METASTATIC BREAST CANCER (MBC)
    Verma, S.
    Zielinski, C.
    Martin, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 98 - 99
  • [5] Phase I clinical trial of bavituximab (Bavi) and paclitaxel (P) patients (pts) with HER2-negative metastatic breast cancer (MBC)
    Chalasani, Pavani
    Marron, Marilyn
    Clarke, Kathryn
    Schmidt, Kathy
    Powell, Alisa
    Iannone, Maria
    Stopeck, Alison
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Safety and immunologic activity of anakinra in HER2-negative metastatic breast cancer (MBC).
    O'Shaughnessy, Joyce
    Young, Robyn R.
    Levin, Maren K.
    Baisch, Jeanine
    Timis, Roxana
    Muniz, Luz Stella
    Turner, Jacob
    Pascual, Virginia
    Palucka, Karolina
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Entinostat, nivolumab and ipilimumab in advanced HER2-negative breast cancer (ETCTN-9844)
    Torres, E. T. Roussos
    Leatherman, J.
    Rafie, C.
    Brufsky, A.
    Lorusso, P.
    Eder, J. P.
    Chung, V.
    Yuan, Y.
    Downs, M.
    O'Connor, A.
    Piekarz, R.
    Streicher, H.
    Rudek, M. A.
    Zhu, Q.
    Fertig, E.
    Anders, R. A.
    Cimino-Mathews, A.
    Jaffee, E. M.
    Stearns, V.
    Connolly, R. M.
    ANNALS OF ONCOLOGY, 2021, 32 : S833 - S833
  • [8] A Phase I Trial of Alpelisib Combined With Capecitabine in Patients With HER2-Negative Metastatic Breast Cancer
    File, Danielle M.
    Abdou, Yara
    Force, Jeremy
    Moore, Dominic T.
    Anders, Carey K.
    Reeder-Hayes, Katherine
    Carey, Lisa A.
    Muss, Hyman B.
    Perou, Charles M.
    Marcom, P. Kelly
    Dees, E. Claire
    CLINICAL BREAST CANCER, 2024, 24 (08) : 683 - 690
  • [9] A phase II study of nivolumab plus ipilimumab and androgen receptor antagonist bicalutamide to stimulate thymic T cell generation in HER2-negative metastatic breast cancer
    Page, David
    Hall, Alexander
    Collins, Krystle
    Moxon, Nicole
    Mellinger, Staci
    Kelly, Tracy
    Kelley, Aysha
    Fredrich, Nicole
    Seino, Amanda
    Liberatore, Gabriella
    Conlin, Alison
    Topp, Zheng
    Perlewitz, Kelly
    Stanton, Sasha
    Urba, Walter
    Wu, Yaping
    Martel, Maritza
    Sun, Zhaoyu
    Kogushi, Yoshinobu
    Redmond, William
    Traina, Tiffany
    Guculp, Ayca
    CANCER RESEARCH, 2024, 84 (09)
  • [10] Treatment of HER2-negative metastatic breast cancer (MBC) with bevacizumab (BEV) plus paclitaxel (TXL): A singlecenter phase II study
    Inno, A.
    Strippoli, A.
    Nazzicone, G.
    Quaranta, A.
    Di Salvatore, M.
    Galiano, A.
    Bagala, C.
    Basso, M.
    Pozzo, C.
    Cassano, A.
    Astone, A.
    Barone, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345